What is blocking CAR-T from scaling to solid tumors?
The biggest obstacle is that solid tumors are not uniform targets. Unlike blood cancers, where a single antigen (like CD19) is present on nearly all malignant cells, solid tumors display a patchwork of different antigens—a problem called antigenic heterogeneity. A 2025 review in *Cancer Cell* explicitly identifies this as a key factor limiting CAR-T effectiveness [1]. A 2023 review on glioblastoma (GBM) adds that tumor plasticity (the ability of cancer cells to change their antigen profile under treatment) drives antigen escape, where the tumor simply stops displaying the target the CAR-T cells are designed to recognize [3]. This means a CAR-T therapy designed for one antigen will miss large parts of the tumor or become obsolete as the tumor evolves.
The second major barrier is the tumor microenvironment (TME). Solid tumors actively suppress immune cells. The same 2025 review notes that the TME is immunosuppressive, causing CAR-T cells to become exhausted and lose their killing ability [1]. For brain tumors like GBM, there is an additional physical barrier: the blood-brain barrier, which makes it difficult for CAR-T cells to even reach the tumor site [3]. A 2026 review on the current state of CAR-T for solid tumors bluntly states that 'their scalability is a major limitation, particularly for solid tumors' [4]. So, the evidence consistently shows that the biology of solid tumors—not manufacturing cost or logistics—is the fundamental reason CAR-T has not scaled.
What new approaches are making scalability more realistic?
Researchers are developing clever workarounds to the antigen-heterogeneity problem. One of the most innovative is the probiotic-guided CAR-T (ProCAR) platform, published in *Science* in 2023. Instead of relying on a single tumor antigen, this system uses engineered bacteria that naturally colonize the immune-privileged cores of solid tumors. These bacteria are programmed to release synthetic targets that 'label' the tumor tissue, essentially painting a bullseye for CAR-T cells to recognize and attack. The study showed this system was 'safe and effective in multiple xenograft and syngeneic models of human and mouse cancers' [2]. This is a fundamentally different approach—it decouples CAR-T targeting from the tumor's own antigens, which could make the therapy applicable to a much wider range of solid tumors.
Another major strategy is combining CAR-T with other treatments to overcome the TME. The 2025 *Cancer Cell* review highlights that pairing CAR-T with immune checkpoint inhibitors (drugs that release the brakes on T cells) can help CAR-T cells resist exhaustion [1]. A 2025 chapter on pancreatic cancer—one of the most treatment-resistant solid tumors—notes that early-phase clinical trials targeting antigens like mesothelin (MSLN) have shown encouraging results, but obstacles like antigen escape and limited T-cell persistence remain [5]. The same chapter emphasizes that modifying the TME through cytokine modulation or checkpoint inhibitors is being actively investigated to boost CAR-T activity [5]. For glioblastoma, a 2023 review reports that combination therapies—such as using multi-antigen-targeted CARs or regional delivery directly into the brain—are showing promise in preclinical and early clinical trials [3]. The emerging picture is that CAR-T alone is unlikely to scale, but CAR-T as part of a combination regimen—or redesigned with platforms like ProCAR—has a clearer path to broader use.
About These Sources
This answer is built on 5 peer-reviewed studies — published from 2023 to 2026, 3 from 2024 or later, 2 in Q1 journals, collectively cited 321 times — selected as the most relevant from 5 studies that passed quality screening, drawn from 19 papers retrieved from a database of over 500 million.
Sources used in this answer
CAR-T therapy in solid tumors
This 2025 review in *Cancer Cell* identifies antigenic heterogeneity and the immunosuppressive tumor microenvironment (TME) as the primary factors limiting CAR-T efficacy in solid tumors, and discusses strategies like multi-antigen targeting and combination with immune checkpoint inhibitors to overcome these barriers.
Probiotic-guided CAR-T cells for solid tumor targeting
This 2023 *Science* study introduces probiotic-guided CAR-T cells (ProCAR), where engineered bacteria colonize tumors and release synthetic targets to label tissue for CAR-mediated lysis, demonstrating safety and efficacy in multiple mouse models of human and mouse cancers.
Insight into the Progress in CAR-T Cell Therapy and Combination with Other Therapies for Glioblastoma
This 2023 review on glioblastoma (GBM) highlights that the blood-brain barrier, immunosuppressive TME, and tumor heterogeneity (including antigen escape) are major obstacles, and reports that combination therapies and multi-antigen-targeted CARs show promise in preclinical and early clinical trials.
Current state of CAR-T cell therapies for solid tumors
This 2026 review on the current state of CAR-T for solid tumors explicitly states that scalability is a major limitation, particularly for solid tumors, without providing specific quantitative data.
Revolutionizing pancreatic cancer treatment with CAR-T therapy
This 2025 chapter on pancreatic cancer notes that early-phase clinical trials targeting antigens like mesothelin (MSLN) have shown encouraging results, but obstacles such as antigen escape and limited T-cell persistence remain, and strategies like TME modification and combination with checkpoint inhibitors are under investigation.